A. D. Beadell Investment Counsel Inc. held its stake in shares of Sanofi SA (NYSE:SNY) during the first quarter, Holdings Channel reports. The fund owned 15,825 shares of the company’s stock at the end of the first quarter. A. D. Beadell Investment Counsel Inc.’s holdings in Sanofi SA were worth $716,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Argentus Capital Management LLC boosted its stake in shares of Sanofi SA by 2.5% in the third quarter. Argentus Capital Management LLC now owns 13,673 shares of the company’s stock worth $522,000 after buying an additional 335 shares during the last quarter. Oxbow Advisors LLC raised its position in Sanofi SA by 0.3% in the third quarter. Oxbow Advisors LLC now owns 84,015 shares of the company’s stock worth $3,210,000 after buying an additional 220 shares in the last quarter. Tocqueville Asset Management L.P. raised its position in Sanofi SA by 5.1% in the third quarter. Tocqueville Asset Management L.P. now owns 268,709 shares of the company’s stock worth $10,262,000 after buying an additional 12,996 shares in the last quarter. Wells Fargo & Company MN raised its position in Sanofi SA by 30.9% in the third quarter. Wells Fargo & Company MN now owns 3,973,784 shares of the company’s stock worth $151,760,000 after buying an additional 938,683 shares in the last quarter. Finally, World Asset Management Inc raised its position in Sanofi SA by 7.4% in the third quarter. World Asset Management Inc now owns 127,983 shares of the company’s stock worth $4,888,000 after buying an additional 8,778 shares in the last quarter. Hedge funds and other institutional investors own 9.63% of the company’s stock.

Institutional Ownership by Quarter for Sanofi SA (NYSE:SNY)

Shares of Sanofi SA (NYSE:SNY) traded down 1.56% during midday trading on Friday, hitting $44.09. 1,715,679 shares of the company’s stock were exchanged. Sanofi SA has a 52 week low of $36.81 and a 52 week high of $45.95. The company has a 50-day moving average of $44.59 and a 200-day moving average of $41.29. The firm has a market cap of $111.35 billion, a price-to-earnings ratio of 22.81 and a beta of 0.98.

Sanofi SA (NYSE:SNY) last announced its quarterly earnings results on Wednesday, February 8th. The company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.01. The firm earned $8.88 billion during the quarter, compared to analysts’ expectations of $9.87 billion. Sanofi SA had a net margin of 13.66% and a return on equity of 26.37%. The company’s quarterly revenue was down 4.3% on a year-over-year basis. Equities research analysts expect that Sanofi SA will post $3.03 EPS for the current fiscal year.

The company also recently declared an annual dividend, which will be paid on Wednesday, June 7th. Shareholders of record on Monday, May 15th will be paid a $1.5771 dividend. The ex-dividend date is Thursday, May 11th. This represents a yield of 3.65%. This is a boost from Sanofi SA’s previous annual dividend of $1.10. Sanofi SA’s dividend payout ratio (DPR) is currently 54.90%.

TRADEMARK VIOLATION NOTICE: “A. D. Beadell Investment Counsel Inc. Holds Position in Sanofi SA (SNY)” was posted by Financial Market News and is the property of of Financial Market News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.financial-market-news.com/2017/04/21/a-d-beadell-investment-counsel-inc-holds-position-in-sanofi-sa-sny.html.

A number of research firms recently commented on SNY. Argus began coverage on shares of Sanofi SA in a research note on Thursday, April 6th. They issued a “buy” rating and a $50.00 price objective for the company. Natixis raised shares of Sanofi SA from a “neutral” rating to a “buy” rating in a research note on Thursday, February 9th. Leerink Swann reaffirmed an “outperform” rating on shares of Sanofi SA in a research note on Tuesday, January 10th. Zacks Investment Research lowered shares of Sanofi SA from a “buy” rating to a “hold” rating in a research note on Monday, February 13th. Finally, Liberum Capital began coverage on shares of Sanofi SA in a research note on Thursday, March 9th. They issued a “hold” rating for the company. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. Sanofi SA presently has an average rating of “Hold” and an average price target of $62.75.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

5 Day Chart for NYSE:SNY

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.